A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue

Thomas C. Shea, Anna Maria Storniolo, James R. Mason, Barbara Newton, Michael Mullen, Raymond Taetle, Mark R. Green

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Twenty patients have received 21 courses of high-dose cyclophosphamide (6 g/m2 over 4 days), etoposide (1,800 mg/m2 over 3 days), and carboplatin (800 to 1,600 mg/m2 by continuous infusion over 96 hours) and autologous bone marrow or peripheral blood stem cell rescue. The maximum tolerated dose of this regimen included these doses of cyclophosphamide and etoposide with a total of 1,600 mg/m2 carboplatin. Acute renal failure was the dose-limiting toxicity and, at the maximum tolerated dose, was observed in two patients of 14 evaluable courses. Nonhematologic toxicity was otherwise modest, and the overall response rate was 70% in patients with a wide variety of solid and hematologic neoplasms.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalSeminars in oncology
Volume19
Issue number1 SUPPL. 2
StatePublished - Feb 1992
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A dose-escalation study of carboplatin/cyclophosphamide/ etoposide along with autologous bone marrow or peripheral blood stem cell rescue'. Together they form a unique fingerprint.

  • Cite this